Previous Article | Next Article ![]()
Journal of Clinical Microbiology, September 2000, p. 3337-3340, Vol. 38, No. 9
LSG & Associates, Diagnostic Medical
Parasitology Consulting/Training Services, Santa Monica,
California,1 and Department of Pathology
and Laboratory Medicine, University of California, Los Angeles,
California2
Received 28 February 2000/Returned for modification 28 March
2000/Accepted 7 June 2000
The Triage parasite panel (BIOSITE Diagnostics, San Diego, Calif.)
is a new qualitative enzyme immunoassay (EIA) panel for the detection
of Giardia lamblia, Entamoeba
histolytica/E. dispar, and Cryptosporidium
parvum in fresh or fresh, frozen, unfixed human fecal specimens.
By using specific antibodies, antigens specific for these organisms are
captured and immobilized on a membrane. Panel performance was evaluated
with known positive and negative stool specimens (a total of 444 specimens) that were tested by the standard ova and parasite (O&P)
examination as the "gold standard," including staining with both
trichrome and modified acid-fast stains. Specimens with discrepant
results between the reference and Triage methods were retested by a
different method, either EIA or immunofluorescence. A number of samples
with discrepant results with the Triage device were confirmed to be
true positives. After resolution of discrepant results, the number of
positive specimens and the sensitivity and specificity results were as follows: for G. lamblia, 170, 95.9%, and 97.4%,
respectively; for E. histolytica/E. dispar, 99, 96.0%, and 99.1%, respectively; and for C. parvum, 60, 98.3%, and 99.7%, respectively. There was no cross-reactivity with
other parasites found in stool specimens, including eight different
protozoa (128 challenges) and three different helminths (83 challenges). The ability to perform the complete O&P examination should
remain an option for those patients with negative parasite panel
results but who are still symptomatic.
With the increasing interest in
rapid diagnostic testing, potential waterborne outbreak situations,
fewer well-trained microscopists, and confirmation that Giardia
lamblia, Entamoeba histolytica/E. dispar,
and Cryptosporidium parvum can cause severe symptoms in humans, laboratories are reviewing their options with regard to immunoassay kits that can be incorporated into their routine testing protocols (2, 4-6, 15, 17-21, 24-27, 32). Not only must these methods be acceptable in terms of sensitivity and specificity but
they must provide clinically relevant, cost-effective, rapid results,
particularly in a potential waterborne outbreak situation (1, 3,
11, 23).
It is well known that protozoan cysts, in particular,
Giardia cysts, are not shed in the stool on a consistent
basis and that their numbers vary from day to day; this is also true of
coccidian oocysts. Examination of stool specimens collected on
consecutive days or even within the recommended 10-day time frame may
not confirm infection with Giardia, E. histolytica/E. dispar, or C. parvum
(13). In patients who are infected with one or more of these
parasites, the use of routine diagnostic methods such as concentration
and trichrome and modified acid-fast staining may be insufficient to
demonstrate the presence of these organisms (16, 33).
Renewed awareness of potential waterborne transmission of these
parasites is based on the number of well-documented outbreaks during
the past few years and the publicity surrounding water regulations and testing.
Among patients with cryptosporidiosis, the majority of immunocompetent
patients have initially been symptomatic, with large numbers of oocysts
present in their stools. In this situation, a number of diagnostic
procedures would be acceptable (8, 12, 13). However, as the
acute infection resolves and the patient becomes asymptomatic, the
number of oocysts dramatically decreases. Also, the number of oocysts
passed by patients, including those with AIDS, varies from day to day
and week to week. It has also been established that the infective dose
of Cryptosporidium oocysts in humans can be relatively low
(7, 10).
Antigen detection assays for G. lamblia, E. histolytica/E. dispar, and C. parvum have
proved to be very useful in the diagnosis of these infections
(4-6, 9, 14-22, 28-31). The advantages of these assays
include labor, time, and batching efficiencies that may lead to
cost reductions. Certainly, these reagents offer alternative methods to
the routine ova and parasite (O&P) examination method and provide the
added sensitivity required to confirm infections in patients with low
parasite numbers.
On the basis of the need for improved diagnostic procedures, a rapid
immunoassay device for the detection of Giardia, E. histolytica/E. dispar, and Cryptosporidium
antigens has been developed (Fig. 1).
This BIOSITE Diagnostics (San Diego, Calif.) Triage rapid qualitative
enzyme immunoassay (EIA) can be performed in approximately 15 min with
fresh or fresh, frozen, unfixed human fecal specimens. This device was
tested against known positive and negative fecal specimens on the basis
of the results of the O&P examination for the detection of G. lamblia and E. histolytica/E. dispar and on the basis of the results of modified acid-fast staining for the detection of C. parvum. Specimens with discrepant results
were retested by EIA or fluorescent-antibody methods.
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Detection of Giardia lamblia,
Entamoeba histolytica/Entamoeba dispar, and
Cryptosporidium parvum Antigens in Human Fecal Specimens
Using the Triage Parasite Panel Enzyme Immunoassay
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (86K):
[in a new window]
FIG. 1.
BIOSITE EIA Triage parasite panel demonstrating positive
results. (A) Positive and negative controls and positive test zone for
G. lamblia (GIARD); (B) positive and negative controls and
positive test zone for E. histolytica/E. dispar
(E. HIST); (C) right, positive and negative controls and positive test
zone for C. parvum (CRYPT).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Specimens.
Fresh, unpreserved stool specimens were used
according to the manufacturer's directions for testing the Triage
parasite panel. Specimens (n = 444) were collected in
clean, leak-proof containers and were frozen and maintained at
20°C
or colder prior to testing. A total of 444 specimens were tested by the
reference methods and with the Triage parasite panel.
Routine O&P examination, modified acid-fast staining examination. Immediately after collection and prior to freezing, a portion of each stool specimen was placed into a vial with 10% formalin and a vial with polyvinyl alcohol. The O&P examination (formalin-ethyl acetate [FeAc] concentration, trichrome staining) and modified acid-fast staining (FeAc concentration, modified acid-fast staining) were considered the reference methods (12, 13). The modified acid-fast stain was prepared from the FeAc concentration sediment (centrifugation at 500 × g for 10 min) (12, 13). Of the 444 specimens examined, a certain number were positive for the following parasites on the basis of the results of the reference methods: Giardia, n = 142 specimens; E. histolytica/E. dispar, n = 42 specimens; and Cryptosporidium, n = 58 specimens. Different parasites (eight protozoa and three helminths; 211 challenges) were also found among the 444 specimens. Specific organisms included Blastocystis hominis (n = 71), Chilomastix mesnili (n = 2), Dientamoeba fragilis (n = 2), Trichomonas hominis (n = 2), Endolimax nana (n = 27), Iodamoeba bütschlii (n = 16), Entamoeba coli (n = 2), Entamoeba hartmanni (n = 6), hookworm eggs (n = 2), Ascaris lumbricoides (n = 74), and Trichuris trichiura eggs (n = 7). Many specimens had multiple parasites, while some were negative for all parasites. Although the results of the O&P examinations were known, the specimens were coded and tested blind when the Triage parasite panel was used.
Specimen preparation for EIA methods. All EIA kits were used with fresh or fresh, frozen stool specimens.
Triage parasite panel. The following immunoassay diagnostic kit was used according to the manufacturer's directions: Triage parasite panel (BIOSITE Diagnostics). Using specific antibodies, antigens specific for Giardia, E. histolytica/E. dispar, and Cryptosporidium are captured and immobilized on a membrane. The assay procedure involves the addition of 4.5 ml of specimen diluent to the specimen tube. Sample (0.5 ml) is added, and the mixture is vortexed for at least 10 s. This diluted, mixed sample is centrifuged at 1,500 × g for at least 5 min. The sample supernatant is poured into the sample filter device and is filtered into the filtrate tube. The filtered sample (0.5 ml) is then added to the center of the test device with a transfer pipette. Enzyme conjugate (140 µl) is added to the center of the membrane. Six drops of wash solution is added to the membrane; this step is repeated once. Then, four drops of the substrate is added to the membrane, followed by a 5-min incubation at 15 to 25°C. The device is then read and the results are interpreted. Positive results are visualized as purple-black lines in the appropriate position in the results window. The tubes, pipettes, devices, and all reagents are provided with the kit. Positive and negative controls are included in the device, and the total time is approximately 15 min.
Testing for resolution of discrepant results. Specimens with discrepant results for G. lamblia and C. parvum were retested by the Alexon-Trend ProSpecT microplate EIA for Giardia and the Meridian Diagnostics Merifluor combination Cryptosporidium-Giardia reagent for G. lamblia and C. parvum. The Alexon-Trend ProSpectT microplate assay for E. histolytica/E. dispar was used to test specimens with discrepant results for this group of organisms.
| |
RESULTS |
|---|
|
|
|---|
EIA for Giardia.
On the basis of the results of the O&P
examination reference method, known positive specimens (G. lamblia, n = 142) and negative samples
(n = 302) were tested by use of the Triage parasite
panel. Additional positive specimens (n = 28) were
identified by using the Triage parasite panel. All specimens with
discrepant results with the Triage parasite panel were retested by the
immunoassay (IA) method designated for discrepancy resolution. If
positive by any two methods, the specimen was considered truly
positive. After resolution, the total number of positive specimens was
170, the sensitivity was 95.9%, the specificity was 97.4%, and the negative predictive value (NPV) was 97.4% (Tables
1 and 2).
|
|
EIA for E. histolytica/E. dispar. On the basis of the results of the O&P examination reference method, positive specimens (E. histolytica/E. dispar, n = 42) and negative samples (n = 401) were tested with the Triage parasite panel; 1 specimen could not be tested; thus, the total was 443. Additional positive specimens (n = 56) were identified with the Triage parasite panel, and one specimen with a false-negative result was seen. All specimens with discrepant results with the Triage parasite panel were retested by the EIA method designated for discrepancy resolution. If positive by any two methods, the specimen was considered truly positive. After resolution, the total number of positive specimens was 99, the sensitivity was 96.0%, the specificity was 99.1%, and the NPV was 98.8% (Tables 1 and 2).
EIA for Cryptosporidium. On the basis of the results of modified acid-fast staining, positive specimens (C. parvum, n = 58) and negative samples (n = 386) were tested with the Triage parasite panel. Additional positive specimens (n = 2) were identified with the Triage parasite panel. All specimens with discrepant results with the Triage parasite panel were retested by immunofluorescence (Tables 1 and 2). If positive by any two methods, the specimen was considered truly positive. After resolution, the number of positive specimens was 60, the sensitivity was 98.3%, the specificity was 99.7%, and the NPV was 99.7%.
| |
DISCUSSION |
|---|
|
|
|---|
The selection of a particular diagnostic kit and approach for incorporation into the work flow should be the responsibility of each laboratory. These decisions are based on a number of factors, including clinical relevance, cost-containment, anticipated workload, ease of kit performance, number of trained staff, single-sample versus batched-sample testing, physician clients, physician ordering patterns, size and configuration of client base, laboratory size, availability of equipment, ease with which a new procedure fits into the routine laboratory work flow, turnaround time for achieving a result, reporting limitations (computer system), and the necessity for staff training and client in-service information distribution.
The rapid immunoassays do not replace routine O&P examinations, but they are very useful when trying to confirm Giardia and Cryptosporidium infections (12). Some laboratories have included both the O&P examination and a Giardia or Cryptosporidium screen in their test menus; both are separate, orderable tests. On the basis of the results of the O&P examination with trichrome stain and the modified acid-fast stain and commercial EIA and immunofluorescence kits for testing of specimens with discrepant results, it is clear that the routine microscopy methods used in this study do not reveal as many positive specimens as the more rapid, newer immunoassay reagents. With the need for strict requirements for specimen collection and fixation, plus the availability of fewer well-trained microscopists who can recognize the subtle differences between organisms for organism differentiation, additional more rapid tests will serve as excellent adjunct methods to the O&P examination, provided that the pros and cons of each approach are clearly recognized. Fecal specimen panels and potential modifications in laboratory test menus should be reviewed in light of these and other published results (2, 4-6, 15, 17-21, 24-33).
It has been reported that the Giardia EIA can detect Giardia in at least 30% more specimens than the microscopic examination (31), and it has been reported to have a sensitivity and specificity of 98 and 100%, respectively (4). In another study, the sensitivity and specificity of ColorPAC (Becton Dickinson) for Giardia detection were 100 and 100%, respectively (15), while an earlier study reported an EIA sensitivity of 97% and a specificity of 96% (30). Other studies reported a range in sensitivity from 91.4 to 100% and a range in specificity from 97.8 to 100% (6). Sensitivities and specificities in studies for the detection of C. parvum have ranged from 66.3 to 100% and 93 to 100%, respectively, with the sensitivities and specificities in the majority of studies ranging from 93 to 100% and 98 to 100%, respectively (2, 15, 16). Various studies looking at antigen detection in stool specimens for the detection of E. histolytica/E. dispar have reported sensitivities and specificities that range from 68.3 to 95% and 97 to 99%, respectively (18, 19, 25, 27). Stool antigen studies for pathogenic E. histolytica provide sensitivities and specificities that range from 87 to 97.6% and 92.6 to 98%, respectively (5, 17, 20, 21).
Although the sensitivities and specificities reported for all of the available immunoassay kits are similar, some formats are more time-consuming and labor-intensive. The ability to concurrently detect and distinguish between G. lamblia, E. histolytica/E. dispar, and C. parvum antigens in fresh or fresh, frozen fecal specimens with a 15-min qualitative EIA panel provides the laboratorian with another very useful diagnostic tool, and this can be accomplished with the BIOSITE Triage parasite panel. The Triage parasite panel procedure is simple to perform, requires minimal training, and can be used for single-specimen or batch-testing approaches. The Triage parasite panel will provide diagnostic laboratories with a simple, convenient, alternative method for performing simultaneous, discrete detection of Giardia-, Cryptosporidium-, and E. histolytica/E. dispar-specific antigens in patient fecal specimens.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: LSG & Associates, Consulting/Training Services, 512-12th St., Santa Monica, CA 90402. Phone: (310) 393-5059. Fax: (310) 899-9722. E-mail: lgarcia1{at}gateway.net.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Addis, D. G., J. P. David, J. M. Roberts, and E. E. Mast. 1992. Epidemiology of Giardiasis in Wisconsin: increasing incidence of reported cases and unexplained season trends. Am. J. Trop. Med. Hyg. 47:13-19. |
| 2. | Arrowood, M. J. 1997. Diagnosis, p. 43-64. In R. Fayer (ed.), Cryptosporidium and cryptosporidiosis. CRC Press, Inc., Boca Raton, Fla. |
| 3. | Atherton, F., C. P. Newman, and D. P. Casemore. 1995. An outbreak of waterborne cryptosporidiosis associated with a public water supply in the UK. Epidemiol. Infect. 115:123-131[Medline]. |
| 4. | Behr, M. A., E. Kokoskin, T. W. Gyorkos, L. Cédilotte, G. M. Faubert, and J. D. MacLean. 1997. Laboratory diagnosis for Giardia lamblia infection: a comparison of microscopy, coprodiagnosis and serology. Can. J. Infect. Dis. 8:33-38. |
| 5. | Bhaskar, S., S. Singh, and M. Sharma. 1996. A single-step immunochromatographic test for the detection of Entamoeba histolytica antigen in stool samples. J. Immunol. Methods 196:193-198[CrossRef][Medline]. |
| 6. |
Boone, J. H.,
T. D. Wilkins,
T. E. Nash,
J. E. Brandon,
E. A. Macias,
R. C. Jerris, and D. M. Lyerly.
1999.
TechLab and Alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1.
J. Clin. Microbiol.
37:611-614 |
| 7. | Chappell, C. L., P. C. Okhuysen, C. R. Sterling, C. Wang, W. Jakubowski, and H. L. DuPont. 1999. Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. parvum serum immunoglobulin G. Am. J. Trop. Med. Hyg. 60:157-164[Abstract]. |
| 8. | Current, W. L., and L. S. Garcia. 1991. Cryptosporidiosis. Clin. Microbiol. Rev. 3:325-358. |
| 9. |
Doing, K. M.,
J. L. Hamm,
J. A. Jellison,
J. A. Marquis, and C. Kingsbury.
1999.
False-positive results obtained with the Alexon ProSpecT Cryptosporidium enzyme immunoassay.
J. Clin. Microbiol.
37:1582-1583 |
| 10. |
DuPont, H. L.,
C. L. Chappell,
C. R. Sterling,
P. C. Okhuysen,
J. B. Rose, and W. Jakubowski.
1995.
The infectivity of Cryptosporidium parvum in healthy volunteers.
N. Engl. J. Med.
332:855-859 |
| 11. | Fayer, R., J. M. Trout, and M. C. Jenkins. 1998. Infectivity of Cryptosporidium parvum oocysts stored in water at environmental temperatures. J. Parasitol. 84:1165-1169[CrossRef][Medline]. |
| 12. | Garcia, L. S. 1999. Practical guide to diagnostic parasitology. ASM Press, Washington, D.C. |
| 13. | Garcia, L. S., and D. A. Bruckner. 1997. Diagnostic medical parasitology, 3rd ed. ASM Press, Washington, D.C. |
| 14. | Garcia, L. S., and R. Y. Shimizu. 1997. Evaluation of nine immunoassay kits (enzyme immunoassay and direct fluorescence) for the detection of Giardia lamblia and Cryptosporidium parvum in human fecal specimens. J. Clin. Microbiol. 35:1526-1529[Abstract]. |
| 15. |
Garcia, L. S., and R. Y. Shimizu.
2000.
Detection of Giardia lamblia and Cryptosporidium parvum antigens in human fecal specimens using the ColorPAC combination rapid solid-phase qualitative immunochromatographic assay.
J. Clin. Microbiol.
38:1267-1268 |
| 16. |
Garcia, L. S.,
A. C. Shum, and D. A. Bruckner.
1992.
Evaluation of a new monoclonal antibody combination reagent for direct fluorescent detection of Giardia cysts and Cryptosporidium oocysts in human fecal specimens.
J. Clin. Microbiol.
30:3255-3257 |
| 17. |
Gonzalez-Ruiz, A.,
R. Haque,
T. Rehman,
A. Aguirre,
A. Hall,
F. Guhl,
D. C. Warhurst, and M. A. Miles.
1994.
Diagnosis of amebic dysentery by detection of Entamoeba histolytica fecal antigen by an invasive strain-specific, monoclonal antibody-based enzyme-linked immunosorbent assay.
J. Clin. Microbiol.
32:964-970 |
| 18. |
Haque, R.,
I. K. Ali,
S. Akther, and W. A. Petri, Jr.
1998.
Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of Entamoeba histolytica infection.
J. Clin. Microbiol.
36:449-452 |
| 19. | Haque, R., L. M. Neville, P. Hahn, and W. A. Petri, Jr. 1995. Rapid diagnosis of Entamoeba infection by using Entamoeba and Entamoeba histolytica stool antigen detection kits. J. Clin. Microbiol. 33:2558-2561[Abstract]. |
| 20. | Haque, R., L. M. Neville, S. Wood, and W. A. Petri, Jr. 1994. Short report: detection of Entamoeba histolytica and E. dispar directly in stool. Am. J. Trop. Med. Hyg. 50:595-596. |
| 21. | Jelinek, T., G. Peyerl, T. Loscher, and H. D. Nothdurft. 1996. Evaluation of an antigen-capture enzyme immunoassay for detection of Entamoeba histolytica in stool samples. Eur. J. Clin. Microbiol. Infect. Dis. 15:752-755[CrossRef][Medline]. |
| 22. | Kehl, K. C., H. Cicirello, and P. L. Havens. 1995. Comparison of four different methods for the detection of Cryptosporidium species. J. Clin. Microbiol. 33:416-418[Abstract]. |
| 23. |
Mackenzie, W. R.,
N. J. Hoxie, and M. E. Proctor.
1994.
A massive outbreak in Milwaukee of Cryptosporidium infection transmitted through the public water supply.
N. Engl. J. Med.
331:161-167 |
| 24. | Marshall, M. M., D. Naumovitz, Y. Ortega, and C. R. Sterling. 1997. Waterborne protozoan pathogens. Clin. Microbiol. Rev. 10:67-85[Abstract]. |
| 25. | Ong, S. J., M. Y. Cheng, K. H. Liu, and C. B. Horng. 1996. Use of the ProSpecT microplate enzyme immunoassay for the detection of pathogenic and non-pathogenic Entamoeba histolytica in faecal specimens. Trans. R. Soc. Trop. Med. Hyg. 90:248-249[CrossRef][Medline]. |
| 26. | Pieniazek, N. J., F. J. Bornay-Llinares, S. B. Slemenda, A. J. da Silva, I. N. S. Moura, M. J. Arrowood, O. Ditrich, and D. G. Addis. 1999. New Cryptosporidium genotypes in HIV-infected persons. Emerg. Infect. Dis. 5:444-449[Medline]. |
| 27. |
Pillai, D. R., and K. C. Kain.
1999.
Immunochromatographic strip-based detection of Entamoeba histolytica-E. dispar and Giardia lamblia coproantigen.
J. Clin. Microbiol.
37:3017-3019 |
| 28. |
Priest, J. W.,
J. P. Kwon,
D. M. Moss,
J. M. Roberts,
M. J. Arrowood,
M. S. Dworkin,
D. D. Juranek, and P. J. Lammie.
1999.
Detection of enzyme immunoassay of serum immunoglobulin G antibodies that recognize specific Cryptosporidium parvum antigens.
J. Clin. Microbiol.
37:1385-1392 |
| 29. |
Rosenblatt, J. E., and L. M. Sloan.
1993.
Evaluation of an enzyme-linked immunosorbent assay for detection of Cryptosporidium spp. in stool specimens.
J. Clin. Microbiol.
31:1468-1471 |
| 30. | Rosenblatt, J. E., L. M. Sloan, and S. K. Schneider. 1993. Evaluation of an enzyme-linked immunosorbent assay for the detection of Giardia lamblia in stool specimens. Diagn. Microbiol. Infect. Dis. 16:337-341[CrossRef][Medline]. |
| 31. |
Rosoff, J. D.,
C. A. Sanders,
S. S. Sonnad,
P. R. De Lay,
W. K. Hadley,
F. F. Vincenzi,
D. M. Yajko, and P. D. O'Hanley.
1989.
Stool diagnosis of giardiasis using a commercially available enzyme immunoassay to detect Giardia-specific antigen 65 (GSA 65).
J. Clin. Microbiol.
27:1997-2002 |
| 32. |
Wolfe, M. S.
1992.
Giardiasis.
Clin. Microbiol. Rev.
5:93-100 |
| 33. | Zimmerman, S. K., and C. A. Needham. 1995. Comparison of conventional stool concentration and preserved-smear methods with Merifluor Cryptosporidium/Giardia direct immunofluorescence assay and ProSpecT Giardia EZ microplate assay for detection of Giardia lamblia. J. Clin. Microbiol. 33:1942-1943[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»